🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Clinical Study of Fundus OCTA for the Identification of CMD

Recruitingn/aAges 18 Years - anyAllPeking University First Hospital
NCT05743140 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Coronary microvascular dysfunction (CMD) carries an increased risk of adverse cardiovascular clinical outcomes. The association between fundus microcirculation changes and coronary microcirculation is not well understood. Optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) is a new type of optical diagnostic imaging technology for non-invasive detection, which can perform multi-dimensional quantitative assessment of fundus microcirculation. In this study, investigators intend to use the coronary angiography-derived index of microvascular resistance (caIMR) to screen patients with CMD, explore the relationship between relevant parameters based on OCT and OCTA measurements and caIMR, and evaluate the feasibility and clinical value of non-invasive identification of CMD through fundus OCT and OCTA.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Patients who underwent coronary angiography in the Department of Cardiology, Peking University First Hospital; 2. Complete baseline clinical information; 3. Subject who have coronary angiography results, which shows coronary stenosis \< 50%; 4. Older than 18 years; 5. Subjects who have signed informed consent. Exclusion Criteria: 1. Present serious fundus disease 2. Severe cataract and other ophthalmic diseases, which affect imaging quality; 3. Target coronary vessels provide collateral circulation for chronic complete occlusive lesions; 4. The target coronary angiography agent is poorly filled, overlapped, or severely distorted, and cannot fully expose the location of the lesion; 5. Coronary angiography images are of poor quality and cannot be identified; 6. Active bleeding state; 7. Severe renal insufficiency, contrast agent allergy, and unable to perform coronary angiography.
💊

What it tests

  • CaIMR
📍

Where

1 site
Peking university first hospital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy